Barchuk, Anton
Bulina, Anna
Cherkashin, Mikhail
Berezina, Natalia
Rakova, Tatyana
Kuplevatskaya, Darya
Stanevich, Oksana
Skougarevskiy, Dmitriy
Okhotin, Artemiy
Funding for this research was provided by:
Polymetal International, plc.
Article History
Received: 28 June 2022
Accepted: 14 September 2022
First Online: 22 September 2022
Declarations
:
: The Ethics Committee of the MIBS approved the VE study on June 21, 2021. The Ethics Committee of the Pavlov First Saint Petersburg State Medical University approved the joint study of COVID-19 VE in St. Petersburg on July 15, 2021. All research was performed following the relevant guidelines and regulations. All participants signed the informed consent upon referral to the LDCT triage. The joint study of COVID-19 vaccine effectiveness in St. Petersburg was registered at ClinicalTrials.gov (NCT04981405, date of registration: August 4, 2021). This publication covers the data collected at the two outpatient centres of the MIBS that contributed to the study data. The Research Planning Board of the European University at St. Petersburg and the Ethics Committee of the Clinic “Scandinavia” approved the seroprevalence study on May 20, 2020 and May 26, 2020, respectively. Consent was obtained from all participants of the study. The study was registered with the following identifiers: Clinicaltrials.gov (NCT04406038, submitted on May 26, 2020, date of registration: May 28, 2020) and ISRCTN registry (ISRCTN11060415, submitted on May 26, 2020, date of registration: May 28, 2020). The data used in this study were anonymized before use.
: Not applicable.
: Anton Barchuk reports personal fees from AstraZeneca, MSD, and Biocad outside the submitted work. Other authors have no conflict of interest or competing interests to declare.